Search Results
Your search for The A,The A matches 32360 pages
Showing 22801 - 22850Making the Most of Poster Sessions
Nathan A. Pennell, MD, PhD, an Associate Professor and Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute and a Poster Walk leader at the 2015 ASCO Annual Meeting, offers advice for anyone planning to attend a Poster Session: Plan ahead. Make sure ...
ASCO’s Patient Resources for Colorectal Cancer Awareness Month
Stock your practice with Cancer.Net resources. Cancer.Net has a comprehensive guide to colorectal cancer at www.cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. You will also find specialized resources for caregiving, survivorship, palliative care, and managing the cost...
2015 Palliative Care in Oncology Symposium Highlights
The Palliative Care in Oncology Symposium, held October 9–10, 2015, in Boston, Massachusetts, brought together more than 670 members of the cancer care community, including oncologists, radiologists, palliative care specialists, nurses, and patient advocates. Sessions delivered information on...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
ASCO Recommends Improvements to Medicare for Managing Multiple Chronic Conditions
ASCO has submitted comments to the U.S. Senate Finance Committee Chronic Care Working Group regarding the Bipartisan Chronic Care Working Group Policy Options document published in December 2015. The society commended the working group for its efforts to improve the Medicare program for...
Conquer Cancer Foundation–Funded Research Published in High-Impact Journals
The Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF) encourages grantees to share the results of their research to help advance progress against cancer. Publication in peer-reviewed journals is one of the most important ways for scientists to achieve recognition. That...
Advanced Imaging May Be Unnecessary for Many Women With Early Breast Cancer, but Rate of Such Testing Remains High
Up to 60% of the computed tomography (CT) scans, bone scans, and positron emission tomography (PET) scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record review, according to the...
ASCO’s Incoming President-Elect Charts His Course for 2017
Bruce E. Johnson, MD, FASCO, was elected ASCO President for the 2017–2018 term this past December and will take office as President-Elect during the ASCO Annual Meeting, June 3–7, 2016, in Chicago. As an ASCO member since 1986, Dr. Johnson brings over 30 years of experience with ASCO to the...
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in ...
Pediatric Oncology Groups Endorse Ethical Framework for Rationing Scarce Drugs
The Children’s Oncology Group (COG) and the American Society of Pediatric Hematology/Oncology (ASPHO) have endorsed formal clinical recommendations for rationing chemotherapy and supportive care agents during times of shortage. The guidance is needed because persistent shortages of many standard...
PET Scan Use in Follow-up Care for Lung and Esophageal Cancer Shows Wide Variation Between Hospitals, No Impact on Survival
A new study suggests that one approach to watching for a cancer's return is being inappropriately used at many hospitals and isn't helping patients survive longer. The findings are published by Healy et al in the Journal of the National Cancer Institute. The study looked at how often survivors ...
Two Forms of Radiosurgery for Brain Metastases Are Equally Effective
While two advanced radiosurgery approaches—Gamma Knife and RapidArc—offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center at Jefferson. Their study, published by Liu et al in Frontiers in Oncology,...
Expert Point of View: Ravi Vij, MD
“These are very exciting data,” said Ravi Vij, MD, Professor of Medicine at Washington University in St. Louis, School of Medicine. “To see such responses in a phase I study in such a relapsed/refractory disease is indeed amazing.” “We have already seen the value of immunomodulatory drugs and...
CAR-T Cell Therapy May Have Role in Treating Multiple Myeloma
Among the burgeoning options for treating multiple myeloma could be an approach that is proving to be exciting in leukemia: CAR-T (chimeric antigen receptor T cells) therapy. Preliminary results of the first-in-humans study in myeloma were presented as a late-breaking abstract at the 2015 ASH...
Survivorship Care in Manitoba: Transition Appointments and Follow-up Care Plans
Working with specialized oncology teams, a provincial agency in Manitoba, Canada, has developed standardized care plans and guidelines for cancer survivors that are implemented in a transition appointment.1 This appointment, which follows the end of active treatment, marks the transfer of medical...
Genomic Alterations in Primary Invasive Lobular Breast Cancer
In a study reported in the Journal of Clinical Oncology, Desmedt et al identified genomic alterations in invasive lobular breast cancer, including several that may serve as targets for current treatment and for treatment research. Invasive lobular breast cancer cells are characterized by...
Expert Point of View: Kathryn Schmitz, PhD, MPH
Discussant Kathryn Schmitz, PhD, MPH, Professor of Epidemiology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, emphasized the compelling body of literature on the efficacy of weight loss and exercise programs for a broad variety of outcomes in the survivorship...
Patient and Provider Engagement With Healthy Lifestyle Information
Most young women diagnosed with breast cancer are not physically active in the months after a cancer diagnosis, but physical activity increased over time. According to data presented at the 2016 Cancer Survivorship Symposium, higher levels of physical activity were seen among women whose oncology...
Expert Point of View: Daniel Hamstra, MD
Formal discussant of these trials Daniel Hamstra, MD, of Texas Center for Proton Therapy, Irving, offered his perspective. With increased doses of radiation using additional conventional fractions, tumor control is improved, but the risk of damage to normal tissue is increased. Hypofractionation is ...
Half of Elderly Patients With Colorectal Cancer Receive Expensive Therapy With Little Survival Benefit
A study published by Bradley et al in Medical Care showed that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2% to 53%. During this period, 1-year treatment costs increased 32% to reach an...
Children With Leukemia From High-Poverty Areas More Likely to Suffer Early Relapse
Among children with acute lymphoblastic leukemia (ALL), the most common pediatric cancer, those who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, despite having received the same treatment, according to new research from Dana-Farber/Boston...
Hypofractionation Is Ready for Prime Time in Prostate Cancer, but Will It Be Adopted?
Separate phase III trials presented at the 2016 Genitourinary Cancers Symposium demonstrated that modest hypofractionated radiotherapy is noninferior to conventional radiotherapy for men with intermediate- and low-risk prostate cancer and should be considered a new standard of care.1,2 However, it...
Mylin A. Torres, MD, Named Director of Winship’s Glenn Family Breast Center
Winship Cancer Institute of Emory University has named Mylin A. Torres, MD, the new Director of the Glenn Family Breast Center, effective January 19, 2016. She succeeds Ruth O’Regan, MD, who now heads the University of Wisconsin Division of Hematology and Oncology. Dr. Torres is Associate Professor ...
Hidayatullah G. Munshi, MD, Named Program Leader of Tumor Environment and Metastasis Program at Robert H. Lurie Comprehensive Cancer Center
Hidayatullah G. Munshi, MD, has been named Leader of the Tumor Environment and Metastasis (TEAM) Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The TEAM Program utilizes an integrative approach to elucidate key molecular interactions between tumor cells and...
Marc S. Ernstoff, MD, Named UB Chief of Hematology/Oncology, Roswell Park Chair of Medicine
Marc S. Ernstoff, MD, has been appointed Professor and Chief of the Division of Hematology/Oncology in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB) and Chair of the Department of Medicine and Senior Vice President of Clinical...
Expert Point of View: Irvin M. Modlin, MD, Lisa Bodei, MD, and Eric Liu, MD
The ASCO Post interviewed Irvin M. Modlin, MD, Emeritus Professor of Gastroenterological Surgery, Yale University School of Medicine, regarding his thoughts on the NETTER-1 results and peptide receptor radionuclide therapies for neuroendocrine tumors. Dr. Modlin led the first study of a peptide...
Study Finds Most Patients With Melanoma Had Few Total Nevi and No Atypical Nevi
Although nevi are considered among the strongest risk factors for melanoma, most patients with melanoma had few total and no atypical nevi, according to a study of 566 patients with invasive cutaneous melanoma. “Three notable findings emerged from this case study,” Alan C. Geller, MPH, ...
Radiolabeled Somatostatin Analog May Represent A Paradigm Change in the Treatment of Neuroendocrine Tumors
A radiolabeled somatostatin analog compound, 177Lu-DOTA0-Tyr3-Octreotate (Lu-177 dotatate), reduced the risk of disease progression or death by 79% in the international phase III NETTER-1 population of previously treated, advanced neuroendocrine tumors of midgut origin.1 Lu-177 dotatate belongs to...
Nuns Work Where None Work
It was December 9, 1975—a cold morning in the tribal village in Mahuadanr in Bihar, India. The valley was filled with an eerie mist coming down from the hills surrounding the village. Champa, a 5-year-old malnourished girl with sunken eyes, an emaciated face, and a huge ascites, was carried by her...
Anamorelin Increases Lean Body Mass in NSCLC Patients With Cachexia
Anamorelin (a ghrelin-receptor agonist) increased lean body mass but had no beneficial effect on handgrip strength vs placebo in patients with advanced non–small cell lung cancer (NSCLC) and cachexia, according to two international phase III trials (ROMANA 1 and 2) reported in The Lancet...
Selective Internal Radiotherapy Does Not Improve Any-Site but Prolongs Liver-Specific Progression-Free Survival in Metastatic Colorectal Cancer
In the phase III SIRFLOX trial reported in the Journal of Clinical Oncology, van Hazel et al found that adding selective internal radiation therapy with yttrium-90 resin microspheres to FOLFOX (fluorouracil, leucovorin, oxaliplatin) with or without bevacizumab (Avastin) did not improve any-site...
ASCO Provides Support and Guidance for the White House Cancer Moonshot Initiative
Although President Richard Nixon signed the National Cancer Act in 1971, essentially declaring a war on cancer, the genesis of the idea had actually been born 2 years earlier, after the first landing on the moon set off a new era of scientific exploration and sparked a belief that any scientific...
Neratinib Shows Some Activity in Previously Treated HER2-Positive Breast Cancer Brain Metastases
In the phase II Translational Breast Cancer Research Consortium (TBCRC) 022 study, reported by Freedman et al in the Journal of Clinical Oncology, the erbB1, HER2, erbB4 inhibitor neratinib showed some activity in patients with HER2-positive breast cancer brain metastases. Study Details In the...
Expert Point of View: Irvin M. Modlin, MD, and Eric Liu, MD
Two neuroendocrine tumor experts had slightly different reactions to the latest RADIANT-4 data. Irvin M. Modlin, MD, Emeritus Professor of Gastroenterological Surgery at Yale University School of Medicine, New Haven, Connecticut, said in an interview that he essentially restricts his use of...
New Staging System for Human Papillomavirus–Related Oropharyngeal Cancer
As reported in The Lancet Oncology by O’Sullivan et al, a new staging system for human papillomavirus–related oropharyngeal cancer has been developed based on findings from the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S) study. Study Details The...
Everolimus Effective in Neuroendocrine Tumors of Gastrointestinal Origin
In a subgroup analysis of the phase III RADIANT-4 trial, focusing on neuroendocrine tumors of gastrointestinal origin, the mTOR inhibitor everolimus (Afinitor) essentially doubled the median progression-free survival time, compared with placebo, researchers reported at the 2016 Gastrointestinal...
Adding Immunotherapy to Radiofrequency Ablation in Colorectal Cancer With Liver Metastasis Shows Promise in Preclinical Models
In a retrospective case-controlled study conducted in patients with colorectal cancer who had received primary tumor resection with or without preoperative radiofrequency ablation for liver metastases, the electrical procedure was found to induce antitumor immune responses in the...
Study Links Normal Stem Cells to Aggressive Prostate Cancer
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer. The study proved that the prostate basal cell layer contains adult stem cells, which possess a unique gene-expression profile resembling the ...
New Biomarker Identifies Uveal Melanoma Patients at High Risk for Metastasis
Among uveal melanomas categorized as class 1, those with high levels of PRAME mRNA were more likely to metastasize than those with low levels of PRAME mRNA, suggesting that patients who have class 1 uveal melanoma with high levels of PRAME mRNA should be monitored more closely for metastatic...
Metabolic Phenotyping of Blood Plasma Allows for the Detection of Lung Cancer
Metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR) identified unique metabolic biomarkers specific to lung cancer patients and allowed for the accurate identification of a cohort of patients with early and late-stage lung cancer. These findings were published by...
Racial/Ethnic Variations in Lung Cancer Incidence and Mortality in the Women’s Health Initiative Study Cohort
As reported by Patel et al in the Journal of Clinical Oncology, analysis of lung cancer incidence and mortality in the Women’s Health Initiative Study cohort of postmenopausal women showed a marginally significant lower risk of cancer in Hispanic women vs white women and no difference in...
Study Finds No Progression-Free Survival Benefit for Weekly Dose-Dense vs Every-3-Week Paclitaxel Plus Carboplatin in Ovarian Cancer
Weekly dose-dense paclitaxel did not provide a progression-free survival benefit over every-3-week paclitaxel in combination with carboplatin and with or without elective bevacizumab (Avastin) in patients with previously untreated ovarian cancer, according to the results of the phase III GOG-0262...
SSO 2016: Federal 'Moonshot' Fight Against Cancer Means More Resources for Surgical Oncology Professionals
The 69th Society of Surgical Oncology (SSO) Annual Cancer Symposium, being held March 2–5 in Boston, will include featured lecturers with ties to the recently announced White House “moonshot” initiative to cure cancer—a proposed $1 billion in spending on cancer research over ...
Light Reflectance Technique May Improve Ability to Remove Prostate Cancer During Surgery
Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery. These findings were reported...
Breast Reconstruction Using Abdominal Tissue: Differences in Outcome With Four Techniques
In women undergoing breast reconstruction using autologous tissue, newer muscle-sparing abdominal flaps can reduce complications while improving some aspects of quality of life, according to a study by Macadem et al in Plastic and Reconstructive Surgery. Comparison of four types of abdominal flaps ...
Asian Trial Finds No Survival Benefit of Adding Gastrectomy to Chemotherapy in Incurable Advanced Gastric Cancer
In the Asian phase III REGATTA trial reported in The Lancet Oncology, Fujitani et al found that the addition of gastrectomy to chemotherapy did not improve overall survival in patients with advanced gastric cancer with a single noncurable factor. Study Details In this open-label trial conducted...
Study Finds 36% Increase in Number of Male Smokers in India Over 17 Years
The number of men smoking tobacco in India rose by more than one third to 108 million between 1998 and 2015, according to a new study published in the journal BMJ Global Health. The study also found that cigarettes were replacing the traditional bidi, a small, inexpensive Indian cigarette,...
Malignant Brain Tumors Most Common Cause of Cancer Deaths in Adolescents and Young Adults
A new report published by Ostrom et al in the journal Neuro-Oncology sponsored by the American Brain Tumor Association (ABTA) found that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39, and the most common cancer occurring...
Factors Associated With Early Mortality in Patients Receiving Adjuvant Therapy for Colon Cancer
In an analysis of the ACCENT (Adjuvant Colon Cancer Endpoints) database reported in the Journal of Clinical Oncology, Cheung et al found that factors associated with early mortality in patients in trials of adjuvant systemic therapy included age, performance status, tumor grade, stage, and ratio of ...
Single-Center Study Evaluates Proton Radiotherapy for Pediatric Medulloblastoma
In a phase II study reported in The Lancet Oncology by Yock et al, use of proton radiotherapy for pediatric medulloblastoma was associated with acceptable long-term toxic effects and good survival outcomes. Study Details In the study, 59 patients aged 3 to 21 years were treated at...
